In one paragraphArticle in Genes & development, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
19 authors.
Gabriel M CohnDepartment of Molecular and Medical Genetics, School of Medicine, Oregon Health and Science University, Portland, Oregon 97239, USA.ORCID 0000-0001-5901-2506 Colin J DanielDepartment of Molecular and Medical Genetics, School of Medicine, Oregon Health and Science University, Portland, Oregon 97239, USA.ORCID 0009-0008-1915-3660 Jennifer R EngDepartment of Molecular and Medical Genetics, School of Medicine, Oregon Health and Science University, Portland, Oregon 97239, USA.ORCID 0000-0003-1499-8417 Alannah S MacDonaldPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 2M9, Canada.ORCID 0009-0003-1971-8143 Jonathan St-GermainPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 2M9, Canada.ORCID 0000-0003-1640-6964 Nadja M PieperDepartment of Biochemistry and Molecular Biology, University of Würzburg, Würzburg 97074, Germany.ORCID 0009-0009-3305-8587 Toshita KannanDepartment of Biochemistry and Molecular Biology, University of Würzburg, Würzburg 97074, Germany.
Xiao-Xin SunDepartment of Molecular and Medical Genetics, School of Medicine, Oregon Health and Science University, Portland, Oregon 97239, USA.ORCID 0000-0002-4607-6604 Carl PelzDepartment of Molecular and Medical Genetics, School of Medicine, Oregon Health and Science University, Portland, Oregon 97239, USA.ORCID 0000-0002-2235-880X Ariffin AliDepartment of Molecular and Medical Genetics, School of Medicine, Oregon Health and Science University, Portland, Oregon 97239, USA.ORCID 0009-0008-7907-8586 Koei ChinCenter for Early Detection Advanced Research, Oregon Health and Science University, Portland, Oregon 97201, USA.ORCID 0000-0001-8061-7462 Alexander SmithBrenden-Colson Center for Pancreatic Care, Oregon Health and Science University, Portland, Oregon 97201, USA.
Charles D LopezBrenden-Colson Center for Pancreatic Care, Oregon Health and Science University, Portland, Oregon 97201, USA.
Jonathan R BrodyBrenden-Colson Center for Pancreatic Care, Oregon Health and Science University, Portland, Oregon 97201, USA.ORCID 0000-0003-3680-3270 Brian RaughtPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 2M9, Canada.ORCID 0000-0001-6145-4776 Linda Z PennPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 2M9, Canada.ORCID 0000-0001-8133-5459 Martin EilersDepartment of Biochemistry and Molecular Biology, University of Würzburg, Würzburg 97074, Germany.ORCID 0000-0002-0376-6533 Mu-Shui DaiDepartment of Molecular and Medical Genetics, School of Medicine, Oregon Health and Science University, Portland, Oregon 97239, USA.ORCID 0000-0001-9031-6962 Rosalie C SearsDepartment of Molecular and Medical Genetics, School of Medicine, Oregon Health and Science University, Portland, Oregon 97239, USA; searsr@ohsu.edu.ORCID 0000-0003-1558-2413 Funding
Understanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Luiz Eduardo Bertassoni · 1997 to 2026
$60.5MHydroxylation regulation of c-MycR01CA186241 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Mu-Shui Dai, ROSALIE C SEARS · 2015 to 2026
$4.2MValidation of novel imaging and molecular tests for early detection of pancreatic cancer through risk-stratified community engagement programsU01CA278923 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Gregory A Cote, Alexander Savio Ramos Guimaraes · 2023 to 2026
$3.3MComparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimensU01CA224012 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI BRODY, JONATHAN, COUSSENS, LISA M. · 2019 to 2023
$2.9MThe Role of post-translational activation of Myc in pancreatic cancerR01CA196228 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI SEARS, ROSALIE C · 2015 to 2019
$2.0MOptimizing anti-wild-type IDH1 therapy in pancreatic cancerR01CA287672 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Jonathan Brody, Jordan M Winter · 2024 to 2026
$2.0MTargeting HuR to improve a synthetic lethal therapy for pancreatic cancerR01CA212600 · NCI · THOMAS JEFFERSON UNIVERSITY · PI BRODY, JONATHAN · 2017 to 2021
$1.9MDeveloping a patient derived model platform to treat BRCA1/2-mutant pancreatic cancersR21CA263996 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI BRODY, JONATHAN, SEARS, ROSALIE C · 2022 to 2023
$370kNCI NIH HHS P30 CA069533NCI NIH HHS R01 CA186241NCI NIH HHS R01 CA196228NCI NIH HHS R01 CA212600NCI NIH HHS R01 CA287672NCI NIH HHS R21 CA263996NCI NIH HHS U01 CA224012NCI NIH HHS U01 CA278923
6 · The paper itselfAbstract
Genomic instability is a hallmark of cancer, driving oncogenic mutations that enhance tumor aggressiveness and drug resistance. MYC, a master transcription factor that is deregulated in nearly all human tumors, paradoxically induces replication stress and associated DNA damage while also increasing expression of DNA repair factors and mediating resistance to DNA-damaging therapies. Emerging evidence supports a nontranscriptional role for MYC in preserving genomic integrity at sites of active transcription and protecting stalled replication forks under stress. Understanding how MYC's genotoxic and genoprotective functions diverge may reveal new therapeutic strategies for MYC-driven cancers. Here, we identify a noncanonical role of MYC in DNA damage response (DDR) through its association with DNA breaks. We show that phosphorylation at serine 62 (pS62-MYC) is crucial for the efficient recruitment of MYC to damage sites, its interaction with repair factors BRCA1 and RAD51, and effective DNA repair to support cell survival under stress. Proteomic profiling of the MYC interactome confirms a conserved interaction with components of the DDR pathway. These findings establish pS62-MYC as a key regulator of genomic stability and a potential therapeutic target in cancers.
Indexed as
DNA Breaks, Double-StrandedDNA RepairProto-Oncogene Proteins c-mycSerineBRCA1 ProteinCell SurvivalDNA DamageHumansPhosphorylationRad51 RecombinaseStress, PhysiologicalBRCA1 ProteinProto-Oncogene Proteins c-mycRad51 RecombinaseSerineDNA damage repairMYCreplication stress
Identifiers
PMID42140671
PMCPMC13322070
What Socratic holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390